Hostname: page-component-8448b6f56d-m8qmq Total loading time: 0 Render date: 2024-04-23T20:09:45.230Z Has data issue: false hasContentIssue false
  • English
  • Français

A systematic review of outcomes in COVID-19 patients treated with western medicine in combination with traditional Chinese medicine versus western medicine alone

Part of: Molecular understanding of Covid pathogenesis, immunity and therapeutics

Published online by Cambridge University Press:  06 January 2022

Ruizhe Yu ,
Shihan Zhang ,
Dejian Zhao  and
Zhanpeng Yuan
Ruizhe Yu
Affiliation:
Department of Preventive Medicine, School of Public Health, Wuhan University, Wuhan, Hubei430071, China
Shihan Zhang
Affiliation:
Department of Preventive Medicine, School of Public Health, Wuhan University, Wuhan, Hubei430071, China
Dejian Zhao
Affiliation:
Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong511430, China
Zhanpeng Yuan*
Affiliation:
Department of Preventive Medicine, School of Public Health, Wuhan University, Wuhan, Hubei430071, China Hubei Provincial Key Laboratory for Applied Toxicology, Wuhan, Hubei430065, China
*
Author for correspondence: Zhanpeng Yuan, E-mail: zpyuan@whu.edu.cn
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Since the outbreak of coronavirus disease 2019 (COVID-19) in late 2019, it has evolved into a global pandemic that has become a substantial public health concern. COVID-19 is still causing a large number of deaths in several countries around the world because of the lack of effective treatment.

Aim

To systematically compare the outcomes of COVID-19 patients treated with integrated Chinese with western (ICW) medicine versus western medicine (WM) alone by pooling the data of published literature, and to determine if ICW treatment of COVID-19 patients has better clinical outcomes.

Methods

We searched PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), China Clinical Trial Registry, Chinese Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI) and Wanfang databases using keywords related to COVID-19, traditional Chinese medicine (TCM) and treatment effect. The search deadline was until 10 February 2021. All randomised controlled (RC) and non-randomised controlled (NRC) clinical trials of the ICW or WM treatment of COVID-19 patients were included. We analysed the effective rate, cure rate, exacerbation rate, turning negative rate of viral nucleic acid, remission rate and remission time of symptoms such as fever, cough, feebleness and chest computed tomography (CT) and the number of white blood cells (WBCs) and lymphocytes (LYM) of the COVID-19 patients. For qualitative and quantitative data, the ratio risk (RR) and weighted mean difference (WMD) were used as the indexes of the statistical analysis, respectively. RevMan 5.4 was used to perform meta-analyses and forest plots with the fixed-effects and random-effects models. Cochrane risk of bias tool (RoB 2.0) was used to assess the risk of bias in the included RC trials, whereas risk of bias in non-randomised studies of interventions was used to assess the risk of bias in NRC trials.

Results

This research includes 16 studies with 1645 valid confirmed COVID-19 patients, among which 895 patients of the experimental group received ICW treatment whereas 750 patients of the control group received WM treatment. The outcomes were assessed in three aspects, that is, overall indicator, symptoms indicator and blood indicator, respectively, and the results showed that the ICW group had better treatment outcomes compared with the WM. Among the overall indicators, the ICW group displayed a higher effective rate (RR = 1.24, 95% confidence interval (CI): 1.16–1.33), clinical cure rate (RR = 1.27, 95% CI: 1.03–1.56) and lower exacerbation rate (RR = 0.36, 95% CI: 0.25–0.52), but no statistical difference was observed in the turning negative rate of viral nucleic acid (RR = 1.20, 95% CI: 0.78–1.85). Among the symptom indicators, the ICW group had a higher fever remission rate (RR = 1.24, 95% CI: 1.09–1.42), less fever remission time (WMD = −1.49, 95% CI: −1.85 to −1.12), a higher cough remission rate (RR = 1.38, 95% CI: 1.10–1.73) and a feebleness remission rate (RR = 1.45, 95% CI: 1.18–1.77), less cough remission time (WMD = −1.61, 95% CI: −2.35 to −0.87) and feebleness remission time (WMD = −1.50, 95% CI: −2.38 to −0.61) and better improvement in chest CT (RR = 1.19, 95% CI: 1.11–1.28). For blood indicator, the number of WBCs in the blood of patients of ICW group rebounded significantly (WMD = 0.35, 95% CI: 0.16–0.54), and the recovery of LYM in the blood was more obvious (WMD = 0.23, 95% CI: 0.06–0.40).

Conclusion

The results of this study show that the outcomes in COVID-19 patients treated by the ICW is better than those treated by the WM treatment alone, suggesting that WM and TCM can be complementary in the treatment of COVID-19.

Keywords

Coronavirus disease 2019 (COVID-19)integrated Chinese with western (ICW)meta-analysistraditional Chinese medicine (TCM)western medicine (WM)
Type
Review
Information
Expert Reviews in Molecular Medicine , Volume 24 , 2022 , e5
Copyright
Copyright © The Author(s), 2022. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

*

These authors contributed equally to this work.

References

World Health Organization. Coronavirus Disease (COVID-19) Dashboard. Available at https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.Google Scholar
The State Council Information Office of the People's Republic of China. Fighting COVID-19: China in Action. June 2020. Available at http://www.scio.gov.cn/zfbps/32832/Document/1681809/1681809.htm.Google Scholar
Zhou, F et al. (2021) Efficacy and safety of Chinese herbal decoction combined with western medicine in treatment of COVID-19: a meta-analysis. Journal of Medical 37, 564–568.Google Scholar
Fan, A et al. (2020) Chinese herbal medicine for COVID-19: current evidence with systematic review and meta-analysis. Journal of Integrative Medicine 18, 385–394.CrossRefGoogle ScholarPubMed
Liu, L et al. (2021) A review and meta-analysis of clinical efficacy and safety of the integrative medicine on COVID-19. Clinical Journal of Chinese Medicine 13, 24–30.Google Scholar
Cai, X et al. (2020) Meta-analysis of the combination of the traditional Chinese and western medicine in the treatment of COVID-19. Journal of Baotou Medical College 36, 95–98.Google Scholar
Ouyang, J et al. (2021) Efficacy and safety of traditional Chinese medicine for patients with mild or common COVID-19: a meta-analysis. Journal of Traditional Chinese Medical Sciences 30, 17–20 + 26.Google Scholar
Chen, L et al. (2020) Retrospective analysis on clinical efficacy of Ganlu Xiaodu decoction combined with western medicine in treatment of common COVID-19 patients. Chinese Journal of Experimental Traditional Medical Formulae 26, 60–67.Google Scholar
Cheng, D et al. (2020) Analysis of curative effect of 51 patients with novel coronavirus pneumonia treated with Chinese medicine Lianhua Qingwen: a multicentre retrospective study. Tianjin Journal of Traditional Chinese Medicine 37, 509–516.Google Scholar
Ding, X et al. (2020) Clinical effect and mechanism of Qingfei Touxie Fuzheng recipe in the treatment of COVID-19. Herald of Med 39, 640–644.Google Scholar
Duan, C et al. (2020) Clinical observation on Jinhua Qinggan granule combined with conventional western medicine therapy in treating mild cases of coronavirus disease 2019. Journal of Traditional Chinese Medicine 61, 1473–1477.Google Scholar
Fu, X et al. (2020) Clinical study on 37 case of COVID-19 treated with integrated traditional Chinese and western medicine. Traditional Chinese Drug Research & Clinical Pharmacology 31, 600–604.Google Scholar
Fu, X et al. (2020) Clinical observation on effect of Toujie Quwen granules in treatment of COVID-19. Chinese Journal of Experimental Traditional Medical Formulae 26, 44–48.Google Scholar
Huang, H et al. (2020) Analysis of traditional Chinese medical syndrome and clinical efficacy of 72 patients with COVID-19. Modern Journal of Integrated Traditional Chinese and Western Medicine 29, 2395–2399 + 2483.Google Scholar
Li, K et al. (2020) Observation on clinical effect of modified Qingfei Paidu decoction in treatment of COVID-19. Chinese Traditional and Herbal Drugs 51, 2046–2049.Google Scholar
Qu, X et al. (2020) Observation on clinical effect of Shufeng Jiedu capsule combined with arbidol hydrochloride capsule in treatment of COVID-19. Chinese Traditional and Herbal Drugs 51, 1167–1170.Google Scholar
Shi, J et al. (2020) Clinical observation on 49 cases of non-critical COVID-19 in Shanghai treated by integrated traditional Chinese and western medicine. Shanghai Journal of Traditional Chinese Medicine 54, 30–35.Google Scholar
Xia, W et al. (2020) Clinical observation on 34 patients with novel coronavirus pneumonia (COVID-19) treated with integrated traditional Chinese and western medicine. Journal of Traditional Chinese Medicine 61, 375–382.Google Scholar
Xiao, Q et al. (2020) Analysis of the value of traditional Chinese medicine Shufeng Jiedu capsules combined with arbidol in the treatment of mild COVID-19. Journal of Traditional Chinese Medical Sciences 29, 756–758.Google Scholar
Yang, M et al. (2020) Multi-center clinical observation of Reyanning mixture in treatment of COVID-19. Chinese Journal of Experimental Traditional Medical Formulae 26, 7–12.Google Scholar
Yao, K et al. (2020) Retrospective clinical analysis on treatment of coronavirus disease 2019 with traditional Chinese medicine Lianhua Qingwen. Chinese Journal of Experimental Traditional Medical Formulae 26, 8–12.Google Scholar
Yu, P et al. (2020) Efficacy of Lianhua Qingwen granules combined with arbidol in the treatment of mild COVID-19. Chinese Pharmaceutical Journal 55, 1042–1045.Google Scholar
Zhang, C et al. (2020) Clinical observation of Xuebijingin the treatment of COVID-19. Chinese Journal of Hospital Pharmacy 40, 964–967.Google Scholar
Sterne, JAC et al. (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366, l4898.CrossRefGoogle ScholarPubMed
Sterne, JA et al. (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355, i4919.CrossRefGoogle ScholarPubMed
State Administration of Medicines and Food Supervision and Administration. Guidelines for Clinical Research of new Chinese Medicines (revised in 2010) [M]. Beijing: China Medical Science and Technology Press.Google Scholar
National Health Commission, State Administration of Traditional Chinese Medicine. New Coronavirus Pneumonia diagnosis and treatment plan (Trial Sixth Edition). [EB/OL]. Available at http://www.gov.cn/zhengce/zhengceku/2020-02/19/content_5480948.htm/2020-02-18/2020-02-26.Google Scholar
Infection and Inflammation Radiology Professional Committee of Chinese Research Hospital Association (2020) Guidelines for imaging aided diagnosis of new coronavirus pneumonia. Chinese Journal of Medical Imaging Technology 3, 321–331.Google Scholar
Huang, C et al. (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England) 395, 497–506.CrossRefGoogle ScholarPubMed
Griffith, JF et al. (2005) Osteonecrosis of hip and knee in patients with severe acute respiratory syndrome treated with steroids. Radiology 235, 168–175.CrossRefGoogle ScholarPubMed
Wang, H et al. (2003) Fatal Aspergillosis in a patient with SARS who was treated with corticosteroids. New England Journal of Medicine 349, 507–508.CrossRefGoogle Scholar
Hong, N et al. (2005) Diffusion-weighted MR study of femoral head avascular necrosis in severe acute respiratory syndrome patients. Journal of Magnetic Resonance Imaging: JMRI 22, 661–664.CrossRefGoogle ScholarPubMed
Shen, J et al. (2004) Report on the investigation of lower extremity osteonecrosis with magnetic resonance imaging in recovered severe acute respiratory syndrome in Guangzhou. National Medical Journal of China 84, 1814–1817.Google ScholarPubMed
Chen, Y et al. (2007) Effect of integrated traditional Chinese medicine and western medicine on the treatment of severe acute respiratory syndrome: a meta-analysis. Journal of Pharmacy Practice 5, 1–9.Google ScholarPubMed
He, D et al. (2004) Treatment of SARS mainly by Chinese herbal drugs: a clinical observation of 34 cases. New Chinese Medicine 12, 20–21.Google Scholar
Perico, L et al. (2021) Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. Nature Reviews. Nephrology 17, 46–64.CrossRefGoogle ScholarPubMed
Nie, X et al. (2021) Multi-organ proteomic landscape of COVID-19 autopsies. Cell 184, 775–791.CrossRefGoogle ScholarPubMed
Cui, X et al. (2018) Baicalein represses TGF-β1-induced fibroblast differentiation through the inhibition of miR-21. Toxicology and Applied Pharmacology 358, 35–42.CrossRefGoogle ScholarPubMed
Sun, X et al. (2020) Baicalein alleviated TGF β1-induced type I collagen production in lung fibroblasts via downregulation of connective tissue growth factor. Biomedicine & Pharmacotherapy 131, 110744.CrossRefGoogle ScholarPubMed
Hu, X and Huang, X (2019) Alleviation of inflammatory response of pulmonary fibrosis in acute respiratory distress syndrome by puerarin via transforming growth factor (TGF-β1). Medical Science Monitor: International Medical Journal of Experimental and Clinical Research 25, 6523–6531.CrossRefGoogle Scholar
Jin, L et al. (2017) Gallic acid attenuates pulmonary fibrosis in a mouse model of transverse aortic contraction-induced heart failure. Vascular Pharmacology 99, 74–82.CrossRefGoogle Scholar
Rong, Y et al. (2018) A novel gallic acid derivative attenuates BLM-induced pulmonary fibrosis in mice. International Immunopharmacology 64, 183–191.CrossRefGoogle ScholarPubMed
Cho, I et al. (2015) Astragalin inhibits autophagy-associated airway epithelial fibrosis. Respiratory Research 16, 51.CrossRefGoogle ScholarPubMed
Xu, L et al. (2014) Total polysaccharide of Yupingfeng protects against bleomycin-induced pulmonary fibrosis via inhibiting transforming growth factor-β1-mediated type I collagen abnormal deposition in rats. Journal of Pharmacy and Pharmacology 66, 1786–1795.CrossRefGoogle ScholarPubMed
Li, L et al. (2015) Total extract of Yupingfeng attenuates bleomycin-induced pulmonary fibrosis in rats. Phytomedicine: International Journal of Phytotherapy and Phytopharmacology 22, 111–119.CrossRefGoogle ScholarPubMed
Cui, W et al. (2015) Total glycosides of Yupingfeng protects against bleomycin-induced pulmonary fibrosis in rats associated with reduced high mobility group box1 activation and epithelial-mesenchymal transition. Inflammation Research 64, 953–961.CrossRefGoogle Scholar
Yang, J et al. (2010) Experimental study on effect of Bufei decoction on TGF-β1 expression in lung tissue of rats with pulmonary fibrosis. Chinese Journal of Traditional Medical Science and Technology 17, 291–292, 303, 280.Google Scholar
Zhang, H et al. (2011) Study on effects of Bufei decoction on MMP-9 and TIMP-1 in lung tissue of pulmonary fibrosis rats. Archives of Traditional Chinese Medicine 29, 2673–2679.Google Scholar
Wang, X et al. (2018) Buyang Huanwu decoction ameliorates bleomycin-induced pulmonary fibrosis in rats via downregulation of related protein and gene expression. Evidence-Based Complementary and Alternative Medicine: ECAM 2018, 9185485.Google ScholarPubMed
Ding, D et al. . (2021) Research progress of traditional Chinese medicine in treating pulmonary fibrosis. Chinese Traditional and Herbal Drugs 1–19. doi: http://kns.cnki.net/kcms/detail/12.1108.R.20210421.1427.002.html.Google Scholar
Leung, E et al. (2020) The scientific foundation of Chinese herbal medicine against COVID-19. Engineering (Beijing) 6, 1099–1107.Google ScholarPubMed
Ma, L et al. (2020) Analysis of the law of traditional Chinese medicine for the treatment of pulmonary fibrosis based on data mining. Chinese Traditional and Herbal Drugs 51, 1406–1411.Google Scholar